Merrem

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Merrem

Property Description
Active ingredient Meropenem (typically as trihydrate)
Form Sterile powder for injection
Pharmacological class Carbapenem (Beta-Lactam) Antibiotic
Common use Treatment of serious bacterial infections
Origin Synthetic compound

Merrem is the former brand name for the medicine containing the active ingredient meropenem, a powerful, synthetic antibiotic. It belongs to the carbapenem group, which is a specialized class of beta-lactam antibiotics known for their broad-spectrum activity and high stability. Meropenem is classified as a critically important antibiotic for human medicine.


What Type of Medicine is Meropenem?

Meropenem is classified as a carbapenem beta-lactam antibiotic, a distinction that is clinically recognized for its efficacy against multi-drug resistant pathogens. This synthetic compound is one of the key agents used in hospitals when dealing with complex, severe infections. Meropenem is distinguished by its high stability against bacterial enzymes, such as beta-lactamases, which would otherwise inactivate the drug. Meropenem functions as a bactericidal agent, meaning it actively kills bacterial cells by interfering with their cell wall synthesis.

What is Meropenem's Pharmaceutical Form and Purpose?

Meropenem is supplied as a sterile powder for injection, categorized as a parenteral formulation that must be administered via intravenous (IV) injection following reconstitution.

Its general purpose is to provide a decisive, broad-acting defense in hospital settings against serious bacterial infections. For instance, meropenem is typically used in a scenario where a patient requires immediate, powerful antibiotic coverage for a suspected severe infection, prior to the exact pathogen being fully identified. This high-value use reflects its status as a reserve antibiotic, leveraged when less potent, first-line treatments are insufficient or inappropriate.

Regulatory References

  1. WHO List of Medically Important Antimicrobials

What side effects are possible with Merrem?

Adverse Reactions and Safety Profile

Contraindications and Serious Warnings

Merrem (meropenem) is contraindicated in patients with a known hypersensitivity to the drug product or any component, or in individuals who have demonstrated a serious, immediate hypersensitivity reaction to other beta-lactam antibiotics (such as penicillins or cephalosporins).

Serious Adverse Reactions reported include potentially fatal hypersensitivity reactions (e.g., anaphylaxis) and severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Seizures and other adverse Central Nervous System (CNS) events have also been reported, particularly in patients with pre-existing CNS disorders or compromised renal function.

Common Side Effects and Other Concerns

The most commonly reported adverse reactions (occurring in ge 2% of adult patients in clinical trials) are typically mild and affect the gastrointestinal, nervous, and hematologic systems. These include headache, nausea/vomiting, diarrhea, constipation, rash, anemia, and inflammation at the injection site.

Of additional concern is the potential for Clostridioides difficile-associated diarrhea (CDAD), which can range from mild to life-threatening colitis, and the risk of thrombocytopenia (low platelet count), especially in patients with renal impairment.

Drug Interaction and Population Considerations

Co-administration with valproic acid or divalproex sodium is not recommended because meropenem can significantly reduce the serum concentration of valproic acid, raising the risk of breakthrough seizures. Dose adjustments are required for adult patients with renal impairment (creatinine clearance le 50 mL/min) to mitigate the risk of adverse CNS events. Monitoring of blood cell counts, liver function, and renal function may be recommended during prolonged therapy.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations of meropenem overdosage and the emergency actions mandated by regulatory authorities.

Property Official Regulatory Information
Documented Overdose Presentations Overdosage is primarily documented to cause clinical signs affecting the Central Nervous System (CNS). These manifestations include the specific occurrence of seizures (convulsions), along with tremors and states of confusion. Laboratory tests may show abnormalities, such as documented increases in blood urea nitrogen and blood creatinine levels.
Population-specific Overdose Notes Regulatory information explicitly states that patients with impaired renal function are at a higher risk of drug accumulation, which can lead to toxicity even at standard dosages due to reduced clearance of the medication from the body.
Emergency-response Statements Individuals must seek immediate medical attention by contacting a poison control center or emergency room at once if an overdosage is suspected or has occurred. The administration of the drug should be reviewed if unexplained neurological events emerge.
Supportive Management Measures Official labeling confirms that no specific antidote is known for meropenem overdosage; therefore, management is limited to symptomatic and supportive treatment. The drug can be efficiently removed from the circulation using haemodialysis or hemofiltration.

Connection to the Official Overdose Profile

The regulatory profile for meropenem overdose centers on the severe clinical outcome of neurotoxicity and the critical importance of patient renal status. Official instructions mandate that urgent medical help must be sought immediately when an overdose is suspected. The documented procedures for management focus on supportive care and the use of procedural interventions like haemodialysis, aligning with the official statement regarding the absence of a specific neutralizing agent.

Therapeutic Uses of Merrem

Quick Facts on Merrem (Meropenem) Uses

  • Adults and Children (3 months and older):
    • Manages complicated intra-abdominal infections.
    • Used for complicated skin and skin structure infections.
  • Children (3 months and older):
    • Administered for the care of bacterial meningitis.

What Merrem Treats: Main Uses and Benefits

Merrem is an important antibacterial agent utilized in healthcare settings for the management of a variety of serious infections caused by susceptible bacteria. Its appropriate use is reserved for conditions where other standard treatments may be unsuitable or less effective.

For adults and pediatric patients aged three months and older, the medication is indicated as a therapeutic option for complicated skin and skin structure infections. This includes conditions such as serious wound or tissue infections that require targeted antimicrobial care. It is also administered for the management of complicated intra-abdominal infections, which can involve conditions like appendicitis and peritonitis.

In the pediatric population (three months of age and older), Merrem is additionally applied for the treatment of bacterial meningitis, an infection of the membranes surrounding the brain and spinal cord.

Merrem is a component of clinical practice guidelines for certain severe infections. Its utility is in helping the patient's biological response address the infection, aligning with established protocols for antimicrobial stewardship.

Eligibility and Restrictions for Use

Who Can and Cannot Use Merrem?

Meropenem’s eligibility is strictly defined by regulatory authorities based on absolute contraindications and conditional use restrictions tied to age and organ function. The medication is contraindicated and must not be used by any patient with a known allergy to Meropenem or a history of severe hypersensitivity (e.g., anaphylaxis) to any other beta-lactam antibiotic (such as penicillins or cephalosporins), as stated in official labeling.


Conditional Eligibility and Restrictions

Population Group Regulatory Status
Approved Age Group Approved for use in adult patients and pediatric patients 3 months of age and older.
Infants (< 3 Months) Use is generally not established and not recommended for most indications, due to insufficient data.
Renal Impairment Adults with impaired kidney function (CrCl le 50 mL/min) are eligible but require dose adjustment. Pediatric patients with renal impairment have no established experience.
CNS Disorders Use requires caution due to a documented increased risk of seizures in patients with central nervous system disorders or a history of seizures.
Pregnancy/Lactation Insufficient human data is available for pregnancy. The drug is excreted in human milk, and use is contingent upon clinical assessment.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for meropenem is defined by several officially documented pharmacokinetic and pharmacodynamic relationships with other substances.

Mandatory Restrictions and Prohibitions

Co-administration is generally not recommended or should be avoided with products containing Valproic Acid or its derivatives (e.g., Divalproex Sodium, Sodium Valproate). This pharmacokinetic interaction officially reduces the serum concentration of valproic acid, a change considered unmanageable by some regulatory authorities. Furthermore, meropenem is subject to contraindication with certain Live Bacterial Vaccines such as the Cholera and BCG Vaccines, due to pharmacodynamic antagonism. The official restriction for the Cholera Vaccine includes a 14-day mandatory separation period before vaccination.

Exposure Alterations and PK Mechanisms

The official prescribing information documents that Probenecid increases the elimination half-life and plasma concentration of meropenem. This effect occurs because Probenecid competitively inhibits renal excretion by blocking active tubular secretion. Additionally, meropenem can affect the exposure of other oral drugs by altering intestinal flora. This includes potentially decreasing the level or effect of oral hormonal contraceptives and potentially increasing the level or effect of oral Digoxin.

Condition-Specific Constraint

For patients whose seizures are stable and controlled by Valproic Acid, regulatory documents note that alternative non-carbapenem antibacterial drugs should be considered due to the officially documented interaction risk.

Mechanism of Action

Irreversible Inhibition of Cell Wall Assembly

Meropenem exerts its effect by acting as an irreversible inhibitor of bacterial enzymes essential for cell wall synthesis, known as Penicillin-Binding Proteins (PBPs). By covalently binding to and permanently inactivating these enzymes, the drug prevents the transpeptidation reaction, which is the final step required for the cross-linking and structural integrity of the peptidoglycan bacterial cell wall.

Bactericidal Effect via Osmotic Lysis

The immediate and complete cessation of cell wall synthesis compromises the bacteria's physical structure, leading to a loss of mechanical strength. This mechanism triggers an osmotic imbalance, causing the bacterial cell to rapidly rupture and die—a cellular action classified as bactericidal. This effect is also facilitated by the drug's structural stability against most common beta-lactamases, which preserves the core PBP inhibition mechanism. The drug's mechanism is functionally constrained by the bacteria's ability to produce enzymes capable of hydrolyzing the beta-lactam ring, such as Metallo- Lactamases (MBLs), or by upregulating efflux pumps.

Dosage and Administration Information

Meropenem (Merrem) is administered strictly via the intravenous (IV) route in a controlled medical setting. The sterile powder requires reconstitution with an appropriate sterile diluent, followed by dilution with an intravenous fluid like 0.9% Sodium Chloride or 5% Dextrose prior to use. The final solution must be visually inspected for particulate matter.

The method and duration of administration depend on the dose and condition. Doses are typically delivered through an IV infusion over a period of 15 to 30 minutes. Alternatively, doses up to 1 gram may be administered as an IV bolus injection over 3 to 5 minutes.

Official Dosing Framework

The established dosing regimen is 8 hourly (three times daily) for all approved indications in adults and pediatric patients ge 3 months. The specific numerical dose is indication-dependent; for instance, complicated intra-abdominal infections typically require 1 gram, while bacterial meningitis may require 2 grams.

A critical procedural instruction is the mandatory adjustment of the dosing interval and/or unit dose for adult patients with renal impairment (Creatinine Clearance le 50 mL/min), a principle not required for hepatic impairment. In pediatric patients, dosing is weight-based (in mg/kg) every 8 hours. The total duration of treatment is determined by the patient's clinical response, not a fixed pre-determined cycle.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Merrem (Meropenem)

Evidence for Complicated Intra-Abdominal Infections (cIAI)

The research base for complicated intra-abdominal infections, such as peritonitis and abscesses, primarily includes short-term randomized controlled trials (RCTs). These randomized trials were structured to evaluate how symptoms change over time. These studies often used a non-inferiority design, meaning researchers aimed to determine if meropenem's performance was similar to, or not substantially worse than, other established broad-spectrum antibiotics. These studies included hospitalized adults and pediatric patients three months of age and older.

Researchers primarily monitored two main areas: clinical status endpoint, which evaluated changes in infection signs and symptoms, and microbiological status endpoint, which tracked the clearance of pathogens. Studies report how symptoms evolved in the observed populations, with many trials describing measurements of clinical status endpoint at the post-treatment follow-up visit that were within the predefined range when compared to the established regimens. Research provides limited information for long-term outcomes or sustained recovery beyond the immediate weeks following the end of treatment.

Evidence for Pediatric Bacterial Meningitis

Meropenem was studied for the treatment of bacterial meningitis in the pediatric population (three months of age and older). The research includes randomized comparative trials against standard treatments, supplemented by Pharmacokinetic/Pharmacodynamic (PK/PD) studies. These PK/PD studies examined temporary physiological imbalance and were used in research exploring how the drug travels through the body to ensure adequate concentration in the cerebrospinal fluid (CSF), which is essential for treating CNS infections.

A critical research limitation is the absence of data for neonates (infants under three months of age). The research findings describe patterns related only to the studied pediatric populations. Research contributes to the broader evidence landscape, but information regarding outcomes far beyond the studied follow-up windows is not fully established.

Research Gaps and Areas of Uncertainty

A major limitation across the research base is the heavy reliance on non-inferiority trials. While these studies help show what has been observed so far, they were not structured to determine if the drug provides better outcomes compared to other treatments. Another significant area of uncertainty is the continued challenge posed by antibiotic resistance. The research is ongoing; therefore, the long-term impact on the effectiveness of meropenem due to the emergence of resistance requires continued scientific monitoring.

Frequently Asked Questions (FAQ)

Common questions about Merrem (FAQ)


Q: What is Merrem used for besides the main things?

In addition to treating complicated intra-abdominal infections and bacterial meningitis, the official labeling for meropenem includes its use for complicated skin and skin structure infections (cSSSI). This indication is approved for both adults and pediatric patients aged three months and older.


Q: Does Merrem make you feel tired or weak?

Regulatory documentation indicates that unusual tiredness or weakness has been reported as a potential adverse reaction to meropenem. These are considered possible side effects that are often brought to the attention of the medical team.


Q: Can Merrem affect your sleep?

Official information notes that meropenem can potentially affect a person's sleep patterns. Side effects such as difficulty falling asleep or staying asleep (insomnia), or even unusual drowsiness or sleepiness, are sometimes reported.


Q: Do I need to change my diet while on Merrem?

The official prescribing information states that patients are generally advised to maintain their normal diet while receiving meropenem. Regulatory information indicates that diet changes are not typically required unless specified by a healthcare provider.


Q: Is Merrem safe for older people or seniors?

Studies reviewed by regulatory bodies have not found specific problems in older populations that would prevent the appropriate use of meropenem. Dose adjustments are mainly required based on kidney function, which is a consideration for all adult patients, including the elderly.


Q: Are there any common foods or drinks that interact with Merrem?

Official safety data includes an interaction warning regarding alcohol consumption while on meropenem, as drinking alcohol can increase the risk of certain side effects. No specific common foods are listed in the official interaction warnings.


Q: Is Merrem ever used for severe skin infections?

Yes, meropenem is officially indicated for the treatment of complicated skin and skin structure infections (cSSSI). This is one of the approved uses of the drug, alongside complicated intra-abdominal infections and meningitis.


Q: Can Merrem affect blood sugar levels?

According to regulatory safety information, meropenem may interfere with certain laboratory tests. Specifically, it has been noted that the drug can cause a false-positive result when checking urine for sugar (glucose) levels.


Q: What are the official warnings about using Merrem with alcohol?

Official warnings state that drinking alcohol while receiving meropenem can increase the risk of experiencing adverse effects. Official guidance emphasizes following specific recommendations from a healthcare team regarding alcohol consumption during therapy.


Q: Does Merrem interact with blood thinners like warfarin?

Regulatory documents indicate that meropenem has been associated with an increased risk of bleeding when it is used alongside certain blood thinners, such as warfarin or acenocoumarol. Official documentation highlights the necessity for medical staff to be aware of all concurrent medications being received.


Q: Does Merrem have a black box warning?

The official prescribing information issued by the U.S. Food and Drug Administration (FDA) for meropenem does not contain a Black Box Warning. A Black Box Warning is the most serious type of cautionary note required by the FDA.


Q: Are there restrictions on driving or operating machinery while receiving Merrem?

Official warnings advise that meropenem may affect mental alertness, coordination, and reaction time in some patients. Official warnings suggest that patients may need to avoid driving or operating complex machinery until any effect on their alertness is known.


Q: What kind of infections does Merrem treat in the lungs?

Official indications for meropenem in some regions include the treatment of pneumonias. This typically covers severe forms of pneumonia, such as nosocomial (hospital-acquired) and ventilator-associated pneumonia.


Q: Is Merrem the same as other 'penem' antibiotics?

Meropenem belongs to a specialized class of antibiotics called carbapenems, which is a subgroup of the 'penem' drugs. Clinical studies comparing meropenem to other drugs in this class, such as imipenem, have noted that meropenem demonstrates greater activity against certain gram-negative pathogens.


Q: Is Merrem a drug that can treat general infections?

Meropenem is classified as a reserve antibiotic and is designated for serious or complicated bacterial infections, such as those in the abdomen or skin, or bacterial meningitis. It is generally not used to treat common or mild infections like simple colds or the flu.


Q: What kind of kidney issues are linked to Merrem?

Official information notes that meropenem is processed and eliminated by the kidneys. Therefore, dose adjustments are required for adult patients who have reduced kidney function (renal impairment) to help prevent the accumulation of the drug, which is associated with an increased risk of central nervous system effects.


Q: Is Merrem considered a 'last resort' antibiotic?

Meropenem is officially designated as a reserve antibiotic and a critically important antibiotic by global health organizations. This classification reflects its use being reserved for situations where less potent, first-line treatments have been found insufficient or are inappropriate.


Q: Does taking Merrem increase the risk of getting other infections, like yeast infections?

The official prescribing information does include a warning about the risk of secondary infections. Specifically, it notes the risk of Clostridioides difficile-associated diarrhea (CDAD), which is a serious infection caused by the overgrowth of a specific bacteria in the gut.


Q: Are there different versions of Merrem treatment?

Yes, official regulatory documents describe different methods of treatment delivery. The drug is administered using different techniques, either as an IV infusion (drip) or a shorter IV bolus injection, and the unit dose can vary depending on the specific type of infection being treated.


Q: What are the reasons someone might stop using Merrem?

Official documents list specific conditions that may necessitate the stopping of the drug. These reasons include the occurrence of serious allergic reactions (like anaphylaxis), severe skin reactions, or adverse central nervous system events such as seizures.


Q: What is the difference between Merrem and Primaxin (Imipenem)?

Both meropenem (Merrem) and imipenem (Primaxin) belong to the carbapenem class of antibiotics. Clinical studies and comparisons noted in official documentation indicate that meropenem typically has greater activity against certain types of gram-negative bacteria than imipenem.


Q: Can a patient be allergic to Merrem without knowing?

Official warnings emphasize that serious allergic reactions are more likely to occur in individuals who have a known history of sensitivity to multiple allergens. Regulatory guidelines stress the necessity of a thorough prior medical history review before administration.

How should Merrem be stored and disposed of?

How to Store and Dispose of Merrem (Meropenem)

The storage of Meropenem is defined by its official regulatory labeling, with different requirements for the sterile powder and the liquid solution.

Storage Requirements

  • Unopened Vial (Powder): The powder for injection must be stored at controlled room temperature, generally below 25 C or 30 C. The product must be kept out of the reach and sight of children.
  • Reconstituted Solution: The solution must not be frozen.

Stability and Handling

Stability is strictly dependent on the diluent and temperature:

Diluent Type Room Temperature Stability (15 C to 25 C) Refrigerated Stability (2 C to 8 C)
0.9% Sodium Chloride Up to 6 hours Up to 12 to 18 hours
5% Dextrose/Glucose Use immediately (e.g., within 30 minutes) Not recommended

Each vial is for single use only. The solution must be visually inspected for particles prior to use.

Disposal

Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste and should not be discarded in wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Merrem found in:

A-Z Index: